Posts Tagged ‘Ozempic’

A Strained Supply of Obesity and Diabetes Meds

November 7, 2022 — There’s a clue in the strained supply of new obesity and diabetes meds that most everyone is missing. For more than a year now, Novo Nordisk has been unable to produce and distribute an adequate supply of semaglutide in the form of Wegovy for the treatment of obesity. This has knock-on effects. So supply of […]

Better Obesity Meds, Murky Supply and Access

October 31, 2022 — One of the themes you will hear when ObesityWeek gets underway tomorrow in San Diego is the dramatic progress that’s coming into view with new obesity drugs. But the picture quickly becomes murky in the real world because of issues with supply and access to these new and improved obesity meds. The access to care […]

Chasing Hoops for Obesity Care

August 1, 2022 — In the New York Times recently, our friend Maya Cohen described her experiences chasing the hoops set before her by health insurance – interfering with medically necessary obesity care. But she did not stop there. She came to the YWM Engage conference to connect with and inspire other advocates for people living with obesity. So […]

Tirzepatide Pricing Comes in Similar to Semaglutide

May 21, 2022 — Competition can be a great thing. In the past few weeks we’ve been hearing a lot about tirzepatide. The FDA just approved it for treating type 2 diabetes, hailing it as an important advance. Tirzepatide for obesity is a couple of years away, but the initial results of pivotal studies have been extremely impressive. So […]

Why Is Semaglutide More Expensive for Obesity?

May 12, 2022 — Somehow this doesn’t seem right. The list price for for a month’s supply of semaglutide when it’s for diabetes is $892. No matter whether you need a dose of 1 mg, or the new high dose of 2 mg, the price is the same. It goes under the brand name of Ozempic and comes from […]

New Semaglutide Dose in Diabetes: Value for Obesity?

March 31, 2022 — This is the kind of change that flies under the radar and makes a big difference. This week, Novo Nordisk received FDA approval of a 2 mg dose of semaglutide (Ozempic®) for better control of type 2 diabetes. This higher dose option provides a means for maintaining better glycemic control in patients as their disease […]

Oral Semaglutide: Diabesity Business As Usual Is Doomed

February 23, 2018 — Wachet auf! As if the clues were not already present, an announcement yesterday makes it plain. Competitors in the sleepy diabesity market had best wake up. The first ever oral GLP-1 agonist for diabetes and obesity – semaglutide – is looking good in clinical trials. That means everyone else had better get serious about innovation. Or risk becoming […]

Semaglutide Approved for Type 2 Diabetes

December 6, 2017 — Late yesterday, a new, once-weekly injection for type 2 diabetes cleared the hurdle of FDA approval for sale. Semaglutide, will be available early next year in a familiar pen injection device. It will come in two doses: 0.5 and 1.0 mg once weekly. For people with type 2 diabetes it’s great to have a once-weekly […]